Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
Stocks in this Quantisnow insightHealth Care
Historical context for MDCX
Across the 26 sessions after earlier MDCX headlines, the stock closed higher 8 times and lower 17 times, with a median move of 5.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MDCX | SPY |
|---|---|---|---|
| Apr 17, 2026 | Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome | +17.0% | +1.2% |
| Apr 15, 2026 | Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression | -25.1% | +0.8% |
| Apr 6, 2026 | Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention | +9.8% | +0.5% |
| Apr 1, 2026 | Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset | -8.5% | +0.8% |
| Mar 30, 2026 | Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate | -9.6% | -0.3% |
| Mar 26, 2026 | Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Planand 1 other headline that session | -5.7% | -1.8% |
Keep researching MDCX
Quantisnow market dataNASDAQ
MDCX
Medicus Pharma Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for MDCX
Full MDCX profile on Quantisnow Follow MDCX and get a push notification the moment its next story breaks.